PURPOSE: To examine the association between beta-blocker (BB) intake, pathologic complete response (pCR) rates, and survival outcomes in patients with breast cancer treated with neoadjuvant chemotherapy. PATIENTS AND METHODS: We retrospectively reviewed 1,413 patients with breast cancer who received neoadjuvant chemotherapy between 1995 and 2007. Patients taking BBs at the start of neoadjuvant therapy were compared with patients with no BB intake. Rates of pCR between the groups were compared using a χ² test. Cox proportional hazards models were fitted to determine the association between BB intake, relapse-free survival (RFS), and overall survival (OS). RESULTS: Patients who used BBs (n = 102) were compared with patients (n = 1,311) who did not. Patients receiving BBs tended to be older and obese (P < .001). The proportion of pCR was not significantly different between the groups (P = .48). After adjustment for age, race, stage, grade, receptor status, lymphovascular invasion, body mass index, diabetes, hypertension, and angiotensin-converting enzyme inhibitor use, BB intake was associated with a significantly better RFS (hazard ratio [HR], 0.52; 95% CI, 0.31 to 0.88) but not OS (P = .09). Among patients with triple-negative breast cancer (TNBC; n = 377), BB intake was associated with improved RFS (HR, 0.30; 95% CI, 0.10 to 0.87;P = .027) but not OS (HR, 0.35; 95% CI, 0.12 to 1.00;P = .05). CONCLUSION: In this study, BB intake was associated with improved RFS in all patients with breast cancer and in patients with TNBC. Additional studies evaluating the potential benefits of beta-adrenergic blockade on breast cancer recurrence with a focus on TNBC are warranted.
PURPOSE: To examine the association between beta-blocker (BB) intake, pathologic complete response (pCR) rates, and survival outcomes in patients with breast cancer treated with neoadjuvant chemotherapy. PATIENTS AND METHODS: We retrospectively reviewed 1,413 patients with breast cancer who received neoadjuvant chemotherapy between 1995 and 2007. Patients taking BBs at the start of neoadjuvant therapy were compared with patients with no BB intake. Rates of pCR between the groups were compared using a χ² test. Cox proportional hazards models were fitted to determine the association between BB intake, relapse-free survival (RFS), and overall survival (OS). RESULTS:Patients who used BBs (n = 102) were compared with patients (n = 1,311) who did not. Patients receiving BBs tended to be older and obese (P < .001). The proportion of pCR was not significantly different between the groups (P = .48). After adjustment for age, race, stage, grade, receptor status, lymphovascular invasion, body mass index, diabetes, hypertension, and angiotensin-converting enzyme inhibitor use, BB intake was associated with a significantly better RFS (hazard ratio [HR], 0.52; 95% CI, 0.31 to 0.88) but not OS (P = .09). Among patients with triple-negative breast cancer (TNBC; n = 377), BB intake was associated with improved RFS (HR, 0.30; 95% CI, 0.10 to 0.87;P = .027) but not OS (HR, 0.35; 95% CI, 0.12 to 1.00;P = .05). CONCLUSION: In this study, BB intake was associated with improved RFS in all patients with breast cancer and in patients with TNBC. Additional studies evaluating the potential benefits of beta-adrenergic blockade on breast cancer recurrence with a focus on TNBC are warranted.
Authors: Monique B Nilsson; Guillermo Armaiz-Pena; Rie Takahashi; Yvonne G Lin; Jose Trevino; Yang Li; Nicholas Jennings; Jesusa Arevalo; Susan K Lutgendorf; Gary E Gallick; Angela M Sanguino; Gabriel Lopez-Berestein; Steven W Cole; Anil K Sood Journal: J Biol Chem Date: 2007-08-23 Impact factor: 5.157
Authors: Robert C Millikan; Beth Newman; Chiu-Kit Tse; Patricia G Moorman; Kathleen Conway; Lynn G Dressler; Lisa V Smith; Miriam H Labbok; Joseph Geradts; Jeannette T Bensen; Susan Jackson; Sarah Nyante; Chad Livasy; Lisa Carey; H Shelton Earp; Charles M Perou Journal: Breast Cancer Res Treat Date: 2007-06-20 Impact factor: 4.872
Authors: Jeong-Won Lee; Mian M K Shahzad; Yvonne G Lin; Guillermo Armaiz-Pena; Lingegowda S Mangala; Hee-Dong Han; Hye-Sun Kim; Eun Ji Nam; Nicholas B Jennings; Jyotsnabaran Halder; Alpa M Nick; Rebecca L Stone; Chunhua Lu; Susan K Lutgendorf; Steve W Cole; Anna E Lokshin; Anil K Sood Journal: Clin Cancer Res Date: 2009-04-07 Impact factor: 12.531
Authors: Amal Melhem; S Diane Yamada; Gini F Fleming; Bertha Delgado; Deanna R Brickley; Wei Wu; Masha Kocherginsky; Suzanne D Conzen Journal: Clin Cancer Res Date: 2009-04-21 Impact factor: 12.531
Authors: Barbara L Andersen; Hae-Chung Yang; William B Farrar; Deanna M Golden-Kreutz; Charles F Emery; Lisa M Thornton; Donn C Young; William E Carson Journal: Cancer Date: 2008-12-15 Impact factor: 6.860
Authors: Jennifer K Litton; Ana M Gonzalez-Angulo; Carla L Warneke; Aman U Buzdar; Shu-Wan Kau; Melissa Bondy; Somdat Mahabir; Gabriel N Hortobagyi; Abenaa M Brewster Journal: J Clin Oncol Date: 2008-09-01 Impact factor: 44.544
Authors: Priya Rastogi; Stewart J Anderson; Harry D Bear; Charles E Geyer; Morton S Kahlenberg; André Robidoux; Richard G Margolese; James L Hoehn; Victor G Vogel; Shaker R Dakhil; Deimante Tamkus; Karen M King; Eduardo R Pajon; Mary Johanna Wright; Jean Robert; Soonmyung Paik; Eleftherios P Mamounas; Norman Wolmark Journal: J Clin Oncol Date: 2008-02-10 Impact factor: 44.544
Authors: S Sud; C O'Callaghan; C Jonker; C Karapetis; T Price; N Tebbutt; J Shapiro; G Van Hazel; N Pavlakis; P Gibbs; M Jeffrey; L Siu; S Gill; R Wong; D Jonker; D Tu; R Goodwin Journal: Curr Oncol Date: 2018-12-01 Impact factor: 3.677
Authors: Kathleen M Kokolus; Ying Zhang; Jeffrey M Sivik; Carla Schmeck; Junjia Zhu; Elizabeth A Repasky; Joseph J Drabick; Todd D Schell Journal: Oncoimmunology Date: 2017-12-21 Impact factor: 8.110
Authors: Anne Kreklau; Ivonne Nel; Sabine Kasimir-Bauer; Rainer Kimmig; Anna Christina Frackenpohl; Bahriye Aktas Journal: In Vivo Date: 2021 Mar-Apr Impact factor: 2.155